Clinical Trials

Carcinoma, Renal Cell

NCT03899155 2026-05-27

Pan Tumor Rollover Study

GastrointestinalGenitourinaryHead & NeckThoracic

1,500 enrolled

Tumor-Agnostic

Neoplasms

NCT05176483 2026-05-27

STELLAR-002

Phase 1 Recruiting

1,314 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT03520686 2026-05-26

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Terminated

102 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03866382 2026-05-26

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

314 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT07293351 2026-05-26

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Phase 1/2 Recruiting

254 enrolled

Carcinoma, Renal Cell

NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

BreastEndocrineGynecologicHead & NeckSarcoma

30 enrolled

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05498792 2026-05-22

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Phase EARLY_PHASE1 Recruiting

12 enrolled

Melanoma

NCT07227415 2026-05-22

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Phase 1/2 Recruiting

224 enrolled

Phase 2 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT07355205 2026-05-22

FLINN

26 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07603856 2026-05-22

REVIVE

39 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02696993 2026-05-20

Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

80 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04388852 2026-05-20

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

65 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Prostatic Neoplasms

NCT04141644 2026-05-19

Osi+Ipi

24 enrolled

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

NCT05779423 2026-05-19

Cryoablation+Ipilimumab+Nivolumab in Melanoma

37 enrolled

Melanoma, Skin Neoplasms

NCT05904080 2026-05-18

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

50 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06365619 2026-05-18

NeoRelapse

25 enrolled

Melanoma

NCT06712927 2026-05-18

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

60 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT07394062 2026-05-18

ALCG-01

Recruiting

400 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02693535 2026-05-15

TAPUR

MyeloidOther hematologic neoplasm

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03600155 2026-05-15

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1 Completed

29 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2 Terminated

225 enrolled

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04003649 2026-05-14

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

20 enrolled

CNS

Glioblastoma

NCT04042753 2026-05-14

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

9 enrolled

Endocrine

Pituitary Diseases, Pituitary Neoplasms

NCT06708949 2026-05-14

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

15 enrolled

Carcinoma, Renal Cell

NCT06946797 2026-05-14

CheckMate-1533

76 enrolled

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07291076 2026-05-14

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Phase 1/2 Recruiting

129 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT07587827 2026-05-14

ODI-2001-01

77 enrolled

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT02339571 2026-05-13

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Phase 2/3 Active not recruiting

600 enrolled

Melanoma

NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

152 enrolled

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT02834013 2026-05-13

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

818 enrolled

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03502733 2026-05-13

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Phase 1/2 Active not recruiting

64 enrolled

Lymphoid

Lymphoma, Neoplasm Metastasis

NCT03604978 2026-05-13

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

38 enrolled

CNS

Meningioma

NCT03793166 2026-05-13

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Phase 3 Active not recruiting

1,175 enrolled